Former DCGI and now advisor to UP CM highlights medical device growth, healthcare expansion, and investment opportunities in the state
The deal brings SAI — a key distributor serving pharmaceutical and nutraceutical manufacturers — into the Safic-Alcan Group’s expanding Asia footprint
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Subscribe To Our Newsletter & Stay Updated
